Age-related macular degeneration

Age-related macular degeneration

Retina and retinal degenerations

The retina is the nerve tissue that "lines" the back of the eye, much like wallpaper. Here, light-sensitive cells (receptors, rods and cones) detect light, similar to the light-sensitive film of the analog camera.

The most common retinal degenerations are macular degeneration, retinitis pigmentosa and Usher syndrome. These diseases cause various degenerations of the light-sensitive cells with different courses. The most common disease of the macula is age-related macular degeneration (AMD).

Age-related macular degeneration (AMD) is the most common cause of visual loss beyond the age of 50 in Switzerland and other industrialized countries. AMD refers to progressive cell damage at the site of sharpest vision, the so-called macula (synonyms macula lutea, yellow spot). As the only part of the retina, only the small macula (2.5-5 mm in diameter) allows us to see details during vision. Without the macula, for example, reading is no longer possible. We can no longer recognize the hands of a clock or faces.

The cause of the disease is a progressive metabolic disorder of the receptors of the retina - caused by aging processes (see dry and wet macular degeneration). In people beyond the age of 60, this macular degeneration poses an immediate threat to a self-determined and independent lifestyle.

Even today, AMD - despite the greatly improved treatment methods - not infrequently leads to the fact that the affected people can no longer fixate and no longer see sharply. Fortunately, a complete loss of visual perception does not normally occur as a result of AMD. At least a roughly orienting "surrounding vision" remains, since the outer part of the retina is not affected by this disease.

The beginning of age-related changes of the retina is the appearance of yellowish deposits, which are called "drusen". A few small drusen do not yet lead to changes in visual acuity. As a rule, these drusen become larger with time and their number increases (so-called maculopathy). This early stage of AMD is usually accompanied by mild, but still disturbing symptoms.

In later stages, there are usually distortions of straight lines (see test Amslernetz) and central failures in the field of vision, which patients notice most clearly when reading.

In advanced stages (late stage macular degeneration) degeneration usually leads to thinning and death of light sensitive cells in the macula (so called dry or atrophic macular degeneration. Patients with this dry (or atrophic) form of macular degeneration complain of an enlarged blind spot in the center of their visual field and often lose their central vision completely in the course.

Another late stage of age-related macular degeneration is the so-called "wet macular degeneration". Deposits disturb the oxygen supply of the macula and the eye reacts with a locally excessive formation of new, but inferior blood vessels (so-called neovascularizations). These damage the metabolism of the retina - increasingly in the area of the macula. In the further course, the area of the macula becomes scarred (so-called fibrovascular scar, Junius-Kuhnt) due to locally excessive inflammatory reactions (excessive activation of the so-called complement system). This leads to rapid central vision loss with loss of reading ability and large central visual field loss.

Once destroyed, it is difficult to restore vision. The only safe and so far approved treatment option for the therapy of wet macular degeneration is a costly but efficient injection therapy. Hereby vascular proliferation inhibiting drugs are given into the vitreous cavity (so called intravitreal injections). The treatment is useful and vision returns as long as no scarring of these pathological vascular membranes has occurred. Therefore, it is very important to make the diagnosis early.

Large studies conducted worldwide have revealed a number of risk factors for retinal aging. Known risk factors that we cannot influence are, besides genetic predisposition, female gender, age, light eye and skin color.

On the other hand there are possibilities to reduce the risk of macular degeneration by influencing the way of life. In numerous studies there is epidemiological evidence for a relationship between age-related macular degeneration (AMD) and excessive sun exposure. For a long time, research assumed that the two pigments lutein and zeaxanthin, which are detectable in high concentrations in the macula, have a protective function. This so-called "macular pigment" absorbs the short-wave sunlight similar to "inner sunglasses" and binds free radicals.

The assumption that late stages can be prevented by increasing the concentration of macular pigment (e.g. via supplementation) has unfortunately only been partially confirmed.

Nevertheless, in order to take advantage of these small positive effects, we recommend optimizing one's lifestyle, especially avoiding tobacco products and paying attention to a healthy diet rich in vitamins and good sun protection.

Instead of excessive daily doses of vitamin supplements (as used e.g. in the American studies), we advise a lutein-rich and seasonal diet. That such a fresh seasonal and regional nutrition does not have to be ascetic, we show with the book "Kochen für die Augen" (published by Bayer (Schweiz) AG in cooperation with Retina Suisse).

This is the first time that we have published a cookbook with recipes in German and French that are not only good for the eyes, but also very tasty and easy to cook.

Cookbook for the eyes

PDF of the book "Kochen für die Augen" (Cooking for the Eyes) by Prof. Dr. med. Ute Wolf-Schnurrbusch and Marc Aeberhard with the support of Retina Suisse (www.retina.ch), photography Peter Dotzauer, publisher and copyright Bayer (Schweiz) AG, Zurich.

eyl_kochbuch_185x290mm_update_2021_online_d_20211130 PDF 14.8 Mb

Therapy options

Examination

In case of familial predisposition, especially a macular degeneration of first-degree family members, a regular routine ophthalmologic examination of the retina is recommended from the age of 50.

 

Therapy

In the course of a wet macular degeneration the eye produces large amounts of the protein VEGF. This protein is one of the most important causes of abnormal, leaky blood vessels. These produce excess fluid, which can lead to swelling of the retina. In recent years, several drugs have been developed that can block the growth factor "VEGF". These drugs - which are also approved in Switzerland and are subject to health insurance coverage - have been shown to normalize the fluid retention and the resulting retinal thickening. Thus, a restoration of visual performance or at least a stabilization of the course of the disease is possible.
The drugs are administered by means of an injection into the vitreous cavity (so-called intravitreal injection) under sterile conditions.

Contact us for a consultation appointment.

Swiss Eye Clinic
Dufourstrasse 47
8008 Zurich

Opening hours:
Monday to Friday 8 till 12 am and 1 till 5 pm

Emergencies possible at any time by telephone arrangement +41 44 923 04 04.

Contact options:
WhatsApp: +41 76 448 35 14
Phone: +41 44 923 04 04
E-mail: swisseyeclinic@hin.ch